Medicamen Biotech Ltd Stock Price Today (NSE: MEDICAMEQ)
Fundamental Score
Medicamen Biotech Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Medicamen Biotech Ltd share price today is ₹223.30, down 4.88% on NSE/BSE as of 30 March 2026. Medicamen Biotech Ltd (MEDICAMEQ) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹545.08 (Cr). The 52-week high for MEDICAMEQ share price is ₹544.00 and the 52-week low is ₹234.40. At a P/E ratio of 50.99x, MEDICAMEQ is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 3.39% and a debt-to-equity ratio of 0.14.
Medicamen Biotech Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Medicamen Biotech Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Medicamen Biotech Share Price: A Financial Analysis
The pharmaceutical industry is currently experiencing a bifurcation, with branded generics and complex formulations driving higher valuations. Assessing the long-term potential of a company requires a granular understanding of its operational efficiency and competitive advantages. This analysis focuses on the current financial standing of Medicamen Biotech share price, which closed at ₹349.549988, derived from a segment of a larger 80-parameter fundamental audit process.
Medicamen Biotech's current Price-to-Earnings (PE) ratio stands at 50.99. To contextualize this, we observe its peers. Comparing management quality, even superficially, reveals differences compared to a behemoth like
Mankind Pharma Ltd. The management quality, the brand recall, and other intangible assets are not explicitly quantified in this analysis, but are important factors.A crucial aspect to consider is Medicamen Biotech's Return on Capital Employed (ROCE) of 5.61%. ROCE reflects how efficiently a company uses its capital to generate profits. This 5.61% ROCE influences the sustainability of the company's economic moat. A low ROCE suggests that the company might face challenges in generating sufficient returns to reinvest in growth and maintain a competitive edge. While this metric does not definitively establish the existence of a moat, it certainly is something to consider for further analysis. Compared to peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, this number provides insights into Medicamen's ability to create shareholder value relative to capital deployed.
This financial analysis is observational and based on publicly available data. It's important to note that this analysis is derived from an 80-parameter fundamental audit and has been reviewed for accuracy by Sweta Mishra. This information should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Medicamen Biotech Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of MEDICAMEQ across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (82.88%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Conservative Debt Levels (D/E: 0.14)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (3.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.61%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 50.99x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-12.51% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-11.81% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-45.97 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.64%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Medicamen Biotech Ltd Financial Statements
Comprehensive financial data for Medicamen Biotech Ltd including income statement, balance sheet and cash flow
About MEDICAMEQ (Medicamen Biotech Ltd)
Medicamen Biotech Ltd is a burgeoning force within the pharmaceutical landscape, operating with a multifaceted approach that encompasses the entire drug lifecycle, from initial res...earch and rigorous development to advanced manufacturing, strategic marketing, and comprehensive global distribution. The company's commitment to innovation is evident in its relentless pursuit of novel formulations and improved delivery systems, positioning it as a key player in meeting the ever-evolving healthcare needs of both domestic and international markets. Their dedication to quality and adherence to stringent regulatory standards underpin every stage of their operations, ensuring the safety and efficacy of their pharmaceutical products. Medicamen Biotech's diverse portfolio caters to a broad spectrum of therapeutic areas, reflecting its comprehensive approach to healthcare solutions. From combating life-threatening diseases like cancer and cardiovascular ailments to managing chronic conditions such as diabetes, the company offers a range of essential medications. Its commitment extends to addressing prevalent health concerns through anti-infectives, anti-malarials, and pain management therapies, alongside vital supplements and vitamins. This expansive array of pharmaceutical formulations underscores Medicamen Biotech's dedication to improving the health and well-being of communities worldwide, demonstrating a clear commitment to serving a wide range of medical needs. The company's success is built on a foundation of robust infrastructure, a skilled workforce, and a relentless focus on customer satisfaction. Leveraging cutting-edge technologies and state-of-the-art manufacturing facilities, Medicamen Biotech strives to optimize production efficiency and maintain consistent product quality. Through strategic partnerships and a well-established distribution network, the company ensures its pharmaceutical products reach patients in need, regardless of geographical location. Medicamen Biotech's unwavering commitment to excellence, innovation, and ethical business practices positions it for continued growth and success in the dynamic pharmaceutical industry.
Company Details
Key Leadership
Corporate Events
MEDICAMEQ Share Price: Frequently Asked Questions
What is the current share price of Medicamen Biotech Ltd (MEDICAMEQ)?
As of 30 Mar 2026, 12:03 pm IST, Medicamen Biotech Ltd share price is ₹223.30. The MEDICAMEQ stock has a market capitalisation of ₹545.08 (Cr) on NSE/BSE.
Is MEDICAMEQ share price Overvalued or Undervalued?
MEDICAMEQ share price is currently trading at a P/E ratio of 50.99x, compared to the industry average of 31.77x. Based on this relative valuation, the Medicamen Biotech Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of MEDICAMEQ share price?
The 52-week high of MEDICAMEQ share price is ₹544.00 and the 52-week low is ₹234.40. These values are updated daily from NSE/BSE price data.
What factors affect the Medicamen Biotech Ltd share price?
Key factors influencing MEDICAMEQ share price include quarterly earnings growth (Sales Growth: 5.43%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Medicamen Biotech Ltd a good stock for long-term investment?
Medicamen Biotech Ltd shows a 5-year Profit Growth of -11.81% and an ROE of 3.39%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.14 before investing in MEDICAMEQ shares.
How does Medicamen Biotech Ltd compare with its industry peers?
Medicamen Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare MEDICAMEQ share price P/E of 50.99x and ROE of 3.39% against the industry averages to determine competitive standing.
What is the P/E ratio of MEDICAMEQ and what does it mean?
MEDICAMEQ share price has a P/E ratio of 50.99x compared to the industry average of 31.77x. Investors pay ₹51 for every ₹1 of annual earnings.
How is MEDICAMEQ performing according to Bull Run's analysis?
MEDICAMEQ has a Bull Run fundamental score of 31.4/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does MEDICAMEQ belong to?
MEDICAMEQ operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Medicamen Biotech Ltd share price.
What is Return on Equity (ROE) and why is it important for MEDICAMEQ?
MEDICAMEQ has an ROE of 3.39%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Medicamen Biotech Ltd generates profits from shareholders capital.
How is MEDICAMEQ debt-to-equity ratio and what does it indicate?
MEDICAMEQ has a debt-to-equity ratio of 0.14, which indicates conservative financing with low financial risk.
What is MEDICAMEQ dividend yield and is it a good dividend stock?
MEDICAMEQ offers a dividend yield of 0.25%, meaning you receive ₹0.25 annual dividend for every ₹100 invested in Medicamen Biotech Ltd shares.
How has MEDICAMEQ share price grown over the past 5 years?
MEDICAMEQ has achieved 5-year growth rates of: Sales Growth 5.31%, Profit Growth -11.81%, and EPS Growth -12.51%.
What is the promoter holding in MEDICAMEQ and why does it matter?
Promoters hold 40.46% of MEDICAMEQ shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Medicamen Biotech Ltd.
What is MEDICAMEQ market capitalisation category?
MEDICAMEQ has a market capitalisation of ₹545 crores, placing it in the Small-cap category.
How volatile is MEDICAMEQ stock?
MEDICAMEQ has a beta of N/A. A beta > 1 suggests the Medicamen Biotech Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is MEDICAMEQ operating profit margin trend?
MEDICAMEQ has a 5-year average Operating Profit Margin (OPM) of 14.92%, indicating the company's operational efficiency.
How is MEDICAMEQ quarterly performance?
Recent quarterly performance shows Medicamen Biotech Ltd YoY Sales Growth of 5.43% and YoY Profit Growth of 82.88%.
What is the institutional holding pattern in MEDICAMEQ?
MEDICAMEQ has FII holding of 0.05% and DII holding of 0.59%. Significant institutional holding often suggests professional confidence in the Medicamen Biotech Ltd stock.